Acumen Pharmaceuticals (ABOS) Income from Continuing Operations (2020 - 2026)
Acumen Pharmaceuticals recorded quarterly Income from Continuing Operations of 21154000.0 in Q1 2026, up 15.26% quarter-over-quarter from 24964000.0 in Q4 2025, and up 26.86% year-over-year from 16675279.04 in Q1 2025.
Acumen Pharmaceuticals' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 21154000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 26.86% year-over-year to 21154000.0; the TTM figure through Mar 2026 stood at 112841000.0 (up 4.31% YoY), while the FY2025 annual figure was 120609000.0, down 16.23% from the prior year.
- Income from Continuing Operations came in at 21154000.0 for Q1 2026 at Acumen Pharmaceuticals, up from 24964000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 9130000.0 in Q1 2022 to a low of 40781000.0 in Q2 2025.
- A 5-year average of 19959058.82 and a median of 15116000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 195.34% in 2022 and soared 33.68% in 2025, its largest moves.
- Acumen Pharmaceuticals' Income from Continuing Operations stood at 12856000.0 in 2022, then fell by 17.58% to 15116000.0 in 2023, then tumbled by 149.02% to 37642000.0 in 2024, then jumped by 33.68% to 24964000.0 in 2025, then grew by 15.26% to 21154000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21154000.0, 24964000.0, and 25942000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Acumen Pharmaceuticals | 164.37 Mn | 35.97 Mn | - | -21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -24.96 Mn |
| Sep 30, 2025 | -25.94 Mn |
| Jun 30, 2025 | -40.78 Mn |
| Mar 31, 2025 | -28.92 Mn |
| Dec 31, 2024 | -37.64 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -21.57 Mn |
| Mar 31, 2024 | -14.77 Mn |
| Dec 31, 2023 | -15.12 Mn |
| Sep 30, 2023 | -12.92 Mn |
| Jun 30, 2023 | -11.59 Mn |
| Mar 31, 2023 | -11.30 Mn |
| Dec 31, 2022 | -12.86 Mn |
| Sep 30, 2022 | -10.71 Mn |
| Jun 30, 2022 | -10.15 Mn |
| Mar 31, 2022 | -9.13 Mn |
| Dec 31, 2021 | -8.35 Mn |
| Sep 30, 2021 | -3.94 Mn |
| Jun 30, 2021 | -3.44 Mn |
| Mar 31, 2021 | -3.79 Mn |
| Dec 31, 2020 | -1.34 Mn |
| Sep 30, 2020 | -2.49 Mn |
| Jun 30, 2020 | -2.04 Mn |